We have previously reported that superoxide stimulates the motility of tumor cells and the administration of Cu-Zn superoxide dismutase (SOD) significantly suppresses metastasis. However, ideally, anti-metastatic therapy should be longlasting, systemically effective and have low toxicity. The halflife of Cu-Zn SOD in plasma is so short that it cannot provide long-lasting effects. Therefore, in this study we have developed a gene therapy in a mouse model utilizing extracellular SOD (EC-SOD), which is the most prevalent SOD
Introduction
Formation of remote metastasis characterizes the malignant feature of cancer and is still a major cause of cancer fatality. Metastasis is comprised of multiple steps of tumor cell behavior including growth and detachment from the primary site, local invasion and destruction of extracellular matrix, intravasation into blood vessels, survival in the circulation, extravasation from the vessels into the metastasis site and growth at the metastasis site.
1,2 Each of these events can occur continually during the process of metastasis, targeting multiple organ sites. Ideally, therefore, anti-metastasis therapy should be longlasting, with systemic effects and low toxicity, which most anticancer modalities are unable to provide, limiting their applicability to metastasis. Radiation, surgery and interventional therapy are not, needless to say, nonsystematic modalities. Anti-cancer drugs may be systemically effective but are often associated with severe adverse side-effects which limit the treatment term, so their efficacy is not long-lasting. Recently, gene therapy has been introduced into the clinical oncology field. However, currently prevailing cancer gene therapies, such as those utilizing the HSVtk gene or p53 gene, are effective only for localized tumors. enzymes have been implicated in the initiation, progression including metastasis and even the prognosis of cancer. [4] [5] [6] Oxygen radicals are produced not only by inflammatory cells such as activated neutrophil and macrophage infiltrating tumor foci, but also tumor cells. 7 We and others have reported that oxygen radicals enhance metastasis in various organs such as lung, 8 liver 9 and bone. 10 We then revealed the fact that superoxide (O − 2 ), a representative oxygen radical, provokes tumor cell motility and invasion as a mechanism by which oxygen radicals promote metastasis. 11 We also disclosed that superoxide dismutase (SOD), a scavenger of superoxide, counteracts this motility. 11, 12 More recently, we disclosed a signaling of protein kinase C to rho family proteins via complex formation with rho GDI as a mechanism underlying the enhanced motility by superoxide (submitted). We also reported the anti-metastatic activity of SOD in both experimental and spontaneous metastatic models with results compatible with the above findings. 8 Takenaga et al 13 confirmed the anti-metastatic effect of SOD and perceived that tumor cell injection caused rapid infiltration of inflammatory cells and excessive free radical production in mouse lung. These facts endorsed the effectivenesss of SOD against metastasis. Unless SOD is used at extremely high levels, it is nontoxic, and therefore is a reasonable candidate for an anti-metastatic agent. 14 In particular, when the anti-metastatic modality is combined with chemotherapy or radiation in a clinical setting where its inertness would not mutually aggravate the adverse effects, it would be most advantageous. In fact, we have confirmed the efficacy of combining Cu-Zn SOD with adriamycin in a metastatic mouse model. 15 However, with regard to practical and clinical applicability, utilizing the SOD protein has an apparent drawback because of its short half-life in the circulation. 14 In the present investigation, therefore instead of the SOD protein, we used the gene of extracellular SOD, which is a secretable isozyme, 16, 17 and retrovirally transfected it into syngeneic fibroblasts ex vivo. Subcutaneous inoculation with these gene-modified fibroblasts yielded elevated levels of circulating SOD for at least 14 days and brought about an efficient reduction of metastasis in both experimental and spontaneous metastatic models.
Results
Detection of EC-SOD cDNA and its m-RNA expression in transfectants Successful transduction and expression of human EC-SOD messenger RNA in BALB-SOD and BDF-SOD was verified by Northern blotting (Figure 1 ). Both of the transfectants exhibited strong 4.3 kb bands that were hybridized with a human EC-SOD probe, while the mock-transfected cells did not.
In vitro proliferation of EC-SOD-transfectants
In vitro doubling time of BALB-SOD cells was 18.8 ± 1.4 h, whereas corresponding untransfected BALB/c 3T3 cells and BALB-mock exhibited 17.3 ± 1.8 h and 17.7 ± 1.5 h, respectively. BDF1-SOD cells exhibited a doubling time (16.3 ± 2.1 h) that was no different from their corresponding untransfected cells (BDF-fibroblasts; 15.9 ± 1.4 h) or the mock-transfected cells (BDF1-mock; 16.0 ± 1.8 h) in culture. These results indicated no apparent effect of the transfection on proliferation of fibroblasts in vitro. (Figure 2b ). These data demonstrate that EC-SOD does not exhibit cytostatic or cytotoxic action against tumor cells in vivo.
EC-SOD activity in culture media of EC-SODtransfected fibroblasts and in plasma of mice inoculated with EC-SOD-transfected fibroblasts The EC-SOD transfectants were examined for their secretion of EC-SOD. The 24 h culture media of BALB- SOD exhibited twice the EC-SOD activity of BALB-mock or BALB/c 3T3 parent cells (Figure 3a) . The 24 h culture media of BDF-SOD also exhibited twice the EC-SOD activity of BDF-mock and BDF-fibroblast parent cells (Figure 3b) .
The plasma EC-SOD activity of the mice inoculated with EC-SOD-transfected fibroblasts was then assayed by the KO 2 method. Three days after the inoculation of BALB-SOD fibroblasts, the mouse plasma EC-SOD activity reached twice the level of BALB-mock-inoculated or BALB 3T3 fibroblast-inoculated mice. This level of activity was maintained for at least 14 days (Figure 3c ). Similar results were obtained in BDF1 mice inoculated with BDF1-SOD fibroblasts (Figure 3d ). results indicate that scavenging superoxide by EC-SOD secreted from transfected fibroblasts counteracts the migration enhancing effect of XOD and HPX.
Figure 3 EC-SOD enzymatic activity in culture media of transfectants and plasma of mice inoculated with transfectants. EC-SOD activity was determined by spectrophotometric assay employing the KO 2 method as described in Materials and methods. EC-SOD enzymatic activity in cell culture media of mock-transfected fibroblasts and EC-SOD gene-transfected fibroblasts. Twenty-four hours after the fibroblasts (5 × 10

Figure 4 Effect of superoxide and EC-SOD supernatant on tumor cell migration. Motility of Meth-A (a) and 3LL (b) was studied using a Transwell double chamber, under the following conditions (as described in Materials and methods): medium alone; medium plus HPX-XOD (`); culture medium of EC-SOD transduced fibroblasts plus HPX-XOD ( ); Bovine Cu-Zn SOD (640 U/ml) plus HPX-XOD (a); culture medium of untransfected fibroblasts (). Values are mean
Histological examination of mouse subcutaneous tissue inoculated with transfectants On day 7 after inoculation of ␤-gal-transfected fibroblasts (1 × 10 7 ), subcutaneous tissue of the mice was resected and microscopically examined. An appreciable number of fibroblasts in sub-dermal tissue which were positive for ␤-galactosidase staining were observed. There was no evident infiltration by inflammatory cells such as neutrophils or lymphocytes into the inoculation site, indicating that EC-SOD-transduced fibroblasts cause no apparent immune response in the host mice (data not shown).
Effect of inoculation of BALB-SOD on experimental metastasis of Meth-A sarcoma cells
Having confirmed the elevation of plasma EC-SOD level in mice which were inoculated with EC-SOD-transfected fibroblasts (Figure 3) , we examined whether the inoculation of gene-modified fibroblasts did indeed suppress metastasis. We first employed an experimental assay by which the prophylactic effect of this modality was examined. On day 0, 1 × 10 7 BALB/3T3 fibroblasts transfected with the EC-SOD gene (BALB-SOD) were s.c. transplanted into the flanks of the mice, and on day 1, Meth-A cells (5 × 10 4 ) were injected via the tail veins. The mice were killed on day 14, and the number of pulmonary metastatic nodules was counted under a dissecting microscope. The experiments were conducted twice independently, and produced similar results. The mice inoculated with BALB-SOD fibroblasts exhibited substantially lower lung metastases than the mice inoculated with BALB-mock fibroblasts ( Table 1) .
Effect of inoculation of BDF-SOD on spontaneous metastasis of Lewis lung carcinoma cells Next, we evaluated the anti-metastatic effect of EC-SODtransfected fibroblasts against spontaneous metastasis from pre-existing tumor foci (prevention effect). In the spontaneous metastasis assay, EC-SOD-transfected BDF1 fibroblasts (BDF1-SOD) were inoculated 3 days after 3LL cells had been transplanted into the right footpad of BDF1 mice. The experiments were conducted twice independently. Both experiments revealed that the mice inoculated with BDF1-SOD fibroblasts exhibited substantially lower lung metastases than the mice inoculated with BDF1-mock fibroblasts ( Table 2) .
Effect of inoculation of BALB-SOD on pre-established experimental metastasis of Meth-A sarcoma cells
We then examined whether the inoculation of gene-modified fibroblasts is effective on pre-established metastasis (Table 3) . EC-SOD BALB fibroblasts were s.c. inoculated 3 days after 5 × 10 4 Meth-A cells were i.v. injected through the tail vein. Mice were killed on day 14, and the number of pulmonary metastatic nodules was counted. The experiments were conducted twice independently. Both experiments disclosed that the inoculation of BALB-SOD fibroblasts caused no appreciable effect on pre-established metastasis (Table 3) .
Discussion
In the present investigation, we demonstrated that inoculation of EC-SOD gene transduced fibroblasts could bring about both prophylactic and preventive effects on lung metastasis by employing experimental and spontaneous metastasis models, respectively.
We also examined the effect of this approach on preestablished metastasis, although the results were indicative of a negative effect, that is, there was no statistically significant suppression of metastasis. However, we believe that this result does not necessarily deny the significance of our approach. Any approaches which are effective on pre-established metastasis should also be effective on primary tumors, and therefore are not considered to be purely anti-metastatic. In other words, pure anti-metastatic approaches are by nature preventive and by no means antitumoral. However, pure anti-metastatic approaches may be beneficial for patients who have not yet developed metastasis at the time of presentation, or for those who already have metastasis at the time of presentation but need to prevent secondary metastasis occur- The BALB/c mice were inoculated with 5 × 10 4 Meth-A cells through the tail vein, followed by s.c. inoculation of EC-SOD gene-transfected fibroblasts. Mice were killed on day 14, and the number of pulmonary metastatic nodules was counted under a dissecting microscope. Results are the mean ± s.d. *Statistically not significant compared with BALB-3T3; **statistically significant (P Ͻ 0.05) compared with BALB-Mock or BALB-3T3. ) were inoculated into the footpad of BDF1 mice. On day 3 and day 9, BDF1-fibroblasts, BDF1-Mock or BDF1-EC-SOD (1.5 × 10 7 ) were s.c. transplanted into the right flank of the mice. On day 10, when the diameter of tumor reached 10 mm, tumor-inoculated feet were amputated under anesthesia. The mice were killed on day 28, and the number of pulmonary metastatic nodules was counted under a dissecting microscope. Results are the mean ± s.d. *Statistically not significant (P Ͻ 0.01) compared with BDF1-fibroblasts; **Statistically significant (P Ͻ 0.01) compared with BDF1-Mock or BDF1-fibroblasts. EC-SOD BALB fibroblasts were s.c. inoculated 3 days after 5 × 10 4 Meth-A cells were i.v. injected through the tail vein. Mice were killed on day 14, and the number of pulmonary metastatic nodules was counted under a dissecting microscope. Results are the mean ± s.d. *Statistically not significant compared with BALB-3T3.
ring from pre-established metastatic sites. In particular, if we consider the clinical difficulty of detecting small metastasis, it would be practical in all cases to use a purely anti-metastatic modality which causes few adverse effects, such as ours, in combination with conventional antitumor strategies.
Gene Therapy SOD itself shows no tumoricidal activity in vitro, nor does it exhibit any antitumor effect in vivo. However, it has clearly suppressed metastasis by inhibiting cell motility 11, 12 and has been clinically proven not to cause any severe side-effects unless an extremely high dosage has been administered. 18 This non-toxic property is essen-tial in an anti-metastatic agent for clinical use since metastasis occurs continuously and requires constant, longterm suppression. In particular, when the anti-metastatic agent is combined with tumoricidal agents such as anticancer drugs, its inertness, in terms of side-effects, is most advantageous. 15 Another requirement for an anti-metastatic agent is a long-lasting effect, as metastasis not only occurs continuously, but also indefinitely. Anti-adhesion peptides have been reported to suppress metastasis, however, they require frequent administration in vivo. 19 Unfortunately, the SOD protein's short half-life in circulation would necessitate continuous infusion of SOD for months or years, rendering it impractical for long-term effectiveness. Although artificial modified SOD such as lecithinized SOD which gives longer retention in plasma has been developed, it peaks in plasma 1 h after administration and declines rapidly in 24 h. 13 Therefore, a gene therapy strategy which facilitates the constant availability of transgene product would be ideal and practical. In the present experiments, we chose an anti-metastatic strategy utilizing syngeneic fibroblasts transfected with the EC-SOD gene. As an alternative target cell, muscle cell is a good candidate since it has been reported to produce a high amount of protein. 20 However, when we conducted muscle transduction with plasmids or liposomes, serum level of SOD was not as high as that achieved in the present report (data not shown). In this context, further elucidation utilizing a cationic liposome, which is reportedly beneficial for muscle transduction, 21 may be needed. Nevertheless, we were able to achieve an increment of EC-SOD in the culture supernatant of transfectants with sufficient activity to suppress O − 2 -induced tumor cell motility. Furthermore, as we initially expected, the elevation of circulating SOD in mice inoculated with gene-modified fibroblasts was maintained for at least 2 weeks. We surmised that this continuity of elevation was a crucial factor in exerting the anti-metastatic effect since the level of SOD in treated mice was only twice that of normal mice. A retroviral vector was used for the transfection of fibroblasts (syngeneic) as the transgene would be integrated into cellular DNA and its expression lasts for a longer period of time. 22 There are several points whereby the EC-SOD gene therapy is superior to other gene therapies. EC-SOD gene therapy works extracellularly, that is, it does not require tumor targeting. This is quite an advantage in that we were able to obtain significant anti-metastatic effects by inoculation of EC-SOD gene-transduced fibroblasts into a region far removed from the primary tumor or metastatic lesions. In other words, the effect is systemic, while current cancer gene therapies rely upon their local antitumor effect. In addition, their effectiveness often varies according to the types of target tumor cells. For example, p53 gene therapy is applied to those tumors with mutated or deleted p53, 23 and immunogene therapy may be effective on immunogenic tumors such as melanoma or renal cell carcinoma. 24, 25 In this context, EC-SOD gene therapy is practicable because of the broad spectrum of tumors against which it can be effective, and also unique in that it does not rely on a direct antitumor effect to suppress metastasis. Another advantageous characteristic of EC-SOD is that it possesses a high affinity to heparan sulfate on the surface of vascular endothelial cells, [26] [27] [28] and therefore, in the micro-environment near the endothelial cell surface on which tumor cells first attach, EC-SOD may be at a higher concentration than found in the blood stream, so the effectiveness may be higher than one may predict from the amount found in the blood stream.
In conclusion, our data indicate that the feasibility of anti-metastatic gene therapy utilizing the EC-SOD gene in humans should be henceforth explored.
Materials and methods
Mouse models Female BDF1 and BALB/c mice, 6 weeks old, were purchased from CLEA Japan (Sendai, Japan). Animals were maintained according to institutional guidelines. All animal experiments were performed under an approval by the Institutional Animal and Care Committee.
Cell culture BALB/c 3T3 fibroblasts (BALB-fibroblasts) were obtained from the Japanese Research Resources Bank (JCRB). Primary BDF1 fibroblasts (BDF1-fibroblasts) were established from BDF1 mouse skin as described later in this section. Both fibroblasts were cultured in dishes (Falcon 3003) in Dulbecco's modified Eagle's medium (D-MEM; Nissui, Tokyo, Japan) supplemented with fetal bovine serum (FBS) (10%), penicillin G and streptomycin (100 U/ml each) in a humidified atmosphere (5% CO 2 , 37°C). A highly metastatic clone of methylcolanthrene-induced fibrosarcoma (Meth-A), which we had previously established, 22 and Lewis lung carcinoma (3LL), which was purchased from ATCC (Rockville, MD, USA), were cultured in flasks (Falcon 3110) in RPMI 1640 medium (Nissui) supplemented with FBS (10%), penicillin G and streptomycin (100 U/ml each) in a humidified atmosphere (5% CO 2 , 37°C).
Preparation of BDF1 primary embryo fibroblasts
On embryonic day E14.5, pregnant DBA/1 mice were dissected, and BDF1 embryos were collected. The embryos were placed under sterile conditions in cold phosphate-buffered saline (PBS), and the internal organs and heads were removed. The remaining torsos were minced and placed into 2 ml of 0.25% trypsin for 30 min at 37°C. The torsos were suspended by pipetting, and the reaction was stopped with an incubation medium (DMEM with 10% fetal calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin). The obtained fibroblasts were washed twice in the DMEM medium and then cultured in DMEM with 10% fetal calf serum. Cells were maintained every 3 days and after eight passages fibroblasts were used as BDF1-fibroblasts.
Construction of retroviral vectors
Human EC-SOD cDNA was obtained from a human placenta cDNA library using reverse transcription-polymerase chain reaction (RT-PCR). For RT-PCR of the human EC-SOD gene, cDNA was synthesized using a first-strand cDNA Synthesis Kit (Boehringer Mannheim, Mannheim, Germany), according to the manufacturer's instructions.
The primers used for PCR corresponded to the sequences located at nucleotides 61-80 (ACTCTAGACAT GCTGGCGCT) and nucleotides 781-803 (AAGCCGCCT GAGCCTGATCAAT) of human EC-SOD. 23 The former primer includes the XbaI restriction site and the latter primer contains the BclI restriction site for cloning into the expression vector. PCR was performed using a PCR kit (Advantage-GC cDNA Polymerase Mix; Clontech, Palo Alto, CA, USA) for 30 cycles, with each cycle consisting of 94°C for 30 s, 60°C for 1 min and 68°C for 1 min. DNA products were separated on an agarose gel, stained with ethidium bromide and detected under UV light. The identity of the amplified products was confirmed by dideoxy sequencing. The retroviral vector, pRx-ZpN, was kindly supplied by Dr Hamada of the Cancer Chemotherapy Center, Japanese Foundation for Cancer Research. 15 Then, the pRx-ZpN vector containing the human EC-SOD cDNA (pRx-ZpNhECSOD) was constructed by inserting human EC-SOD cDNA into the XbaI and BamI sites in place of the lacZ gene. As a mock control vector, pRx-ZpN was used.
Transduction of EC-SOD gene into fibroblasts
The pRx-ZpNhECSOD and pRx-ZpN were each transfected into the ecotropic retroviral packaging cell line BOSC23 by the calcium phosphate precipitation method to obtain the retroviral supernatant. 24 The BALB-fibroblasts and BDF1-fibroblasts were infected with 2 ml of filtered retroviral supernatants in the presence of Polybrene (Sigma, St Louis, MO, USA; 8 g/ml), and the transfectants were selected by G-418 (Gibco BRL, Grand Island, NY, USA; 1 mg/ml).
In vitro proliferation of EC-SOD-transfectants
In vitro doubling time of fibroblasts were assayed by culturing the cells in vitro in the culture dishes (Falcon 3003) and counting the cell number during the exponential growth phase at 8 h intervals.
PCR for EC-SOD and neomycin-resistant genes DNA was extracted from 1 × 10 7 transfected fibroblasts using a QIAamp Blood Kit (Qiagen, Valencia, CA, USA). The human EC-SOD cDNA and neomycin-resistant gene were detected by the PCR method. For RT-PCR of the human EC-SOD gene, the primers corresponding to the EC-SOD nucleotides 61-80 (ACTCCAGCCATGCTGG CGCT) and nucleotides 781-803 (AAGGCCGCCTGAGC GCGGCCCCC) were used. For amplification of the neomycin-resistant (neo R ) gene, the primers corresponding to the neo R nucleotide sequence 2-21 (ATCTGATCAAGA GACAGG AT) and 398-418 (GCCGACGTATGCGAACT AGG) were used. PCR was performed using a PCR kit (Advantage-GC cDNA Polymerase Mix; Clontech) for 30 cycles, with each cycle consisting of 94°C for 30 s, 60°C for 1 min and 68°C for 1 min. DNA products were separated on an agarose gel, stained with ethidium bromide and detected under UV light.
Northern blot analysis
Total RNA was extracted from 2 × 10 8 of each fibroblast, then poly(A+) messenger RNA was retrieved by a messenger RNA isolation Kit (Stratagene, La Jolla, CA, USA). One g of messenger RNA was separated on an 1.0% agarose gel containing 2.2 m formaldehyde, transferred on to a nitrocellulose filter (Schleicher and Schuell, Dassel/Ralliehausen, Germany), and hybridized with an EC-SOD probe which was 32 P-radiolabeled by the random primer method in hybridization solution (50% forGene Therapy mamide, 4 × SSPE, 2 × Denhardt's solution, 0.1% SDS and 2 mg/ml denatured salmon sperm DNA) at 94°C for 16 h. The filter was washed, heat dried and subjected to autoradiography.
Assay for EC-SOD activity EC-SOD activity in cell culture media and plasma was assayed according to the method described by Marklund. 25 Briefly, a sample (150-1000 l) was applied to a Con A-Sepharose column (Pharmacia, Peapack, NJ, USA) which had been equilibrated with PBS. The column was then washed with PBS, and EC-SOD which bound to the column was eluted with 0.5 m methylmannoside. SOD activity in the eluate was determined by measuring the absorbance at 250 nm. One unit of SOD activity was defined as the amount of protein in the solution necessary to decrease the reference rate of NBT reduction by 50%. was generated in the upper chamber by co-incubating XOD (2 × 10 −4 units/ml) with HPX (1 mg/ml). The cells were incubated at 37°C (5% CO 2 ) for 12 h; after that the cells in both chambers were lysed with 1 n NaOH, and the radioactivity was counted in a gamma counter. Cell motility was expressed as the ratio of the counts in the lower chamber to that of total cells in the chamber.
Radiolabeling of tumor cells
Histochemical detection of ␤-gal enzymatic activity The mice were killed 7 days after the inoculation of mock vector-transfected fibroblasts (1 × 10 7 per mouse); the skins were removed, fixed in 4% paraformaldehyde for 30 min, embedded in Tissue-Tek (Sakura, Torrance, CA, USA) and frozen in liquid nitrogen until processed. The tissue was then cut on a cryostat, rinsed in phosphatebuffered saline (PBS) three times, incubated at 37°C overnight in X-gal/Fe solution (5 mm K 3 Fe(CN) 6 Spontaneous pulmonary metastasis assay of 3LL On day 0, 3LL cells (8 × 10 5 ) were inoculated into the footpad of BDF1 mice. On day 3 and day 9, 1.5 × 10 7 of BDF1 fibroblasts transfected with the EC-SOD gene (BDF-SOD) were s.c. transplanted into the right flank of the mice. On day 10, when the diameter of the tumors reached 10 mm, tumor-inoculated feet were amputated under anesthesia. The mice were killed on day 28, and the number of pulmonary metastatic nodules was counted under a dissecting microscope.
Statistical analysis
Statistical analysis of the data was performed by standard techniques with the aid of the Stat View computer program for Macintosh (Abacus Concepts, Berkeley, CA, USA). Two-factor ANOVA was used to compare the difference between the two factors. The means are provided with associated standard deviations (s.d.). Statistical significance was P Ͻ 0.05.
